ZB 006
Alternative Names: ZB006Latest Information Update: 28 Apr 2025
At a glance
- Originator Dianthus Therapeutics
- Developer Zenas BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Autoimmune-disorders in China (Parenteral)
- 28 Apr 2025 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 29 May 2021 Zenas Biopharma plans a clinical trial for Autoimmune disorders in 2023 (Zenas Biopharma pipeline, May 2021)